Answers are grounded in this paper and cite their sources.
RSClinN+ provides improved estimates of prognosis and absolute CET benefit for individual patients compared with RS or with clinical data alone and could be used in patient counseling.
No takes yet. Share an insight, caveat, or question.
Pusztai et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: